# NRG Oncology Network Group Operations Center

> **NIH NIH U10** · NRG ONCOLOGY FOUNDATION, INC. · 2020 · $140,205

## Abstract

NRG Overall Component Abstract
NRG Oncology (NRG) has made significant progress toward its goal of improving the lives of
adults with certain non-hematologic malignancies through its clinical and translational research
efforts. NRG's defined patient populations of interest - those with gender-specific malignancies
and/or those with localized or locally advanced disease, are unique within the NCTN,
constituting a large and relatively under-investigated cohort of cancer patients. Positioned to be
the lead NCTN research organization for trials enrolling several patient cohorts, NRG's portfolio
focuses on patients with gynecologic cancer, primary or secondary brain tumors, head and neck
cancer, or localized or locally advanced prostate cancer as well as breast cancer, lung cancer,
gastrointestinal cancer, bladder cancer, or sarcoma. In these and other realms NRG, actively
collaborates with other NCTN groups, diligently working to increase awareness of and
participation in all NCTN trials.
NRG's research accomplishments to date have been extraordinary. There have been 87 CTEP-
supported NRG trials open for enrollment during this period, representing 34% of the open
NCTN adult trials. For the period March 1, 2014 through August 31, 2017, NRG members
entered 10,840 patients onto NRG-led trials, 3,199 patients into trials led by other NCTN
network groups, and an additional 1,906 patients onto NCTN Precision Medicine Trials for a
total of 15,945 entries. Of the 48,056 total NCTN treatment enrollments, NRG's contribution
accounts for 33% of the total entries and represents the largest accrual of any of the five NCTN
groups. Of patients enrolled onto NRG trials at U.S. sites, 12.7% were self-identified as of
African descent and 8.0% as Latino or Hispanic.
There have been 302 NRG peer-reviewed manuscripts published or in press and 365 published
abstracts during this period, of which at least 52 contain practice-changing or practice-defining
observations. To successfully fulfill its ambitious goal, NRG has seven cancer disease site
committees, all with internationally recognized multi-disciplinary leadership and all with strong
liaison representatives from NRG's nine scientific core committees. There are four other
protocol-generating committees and five administrative committees, all designed to lead and
support critical areas of the group's research. NRG is organized such that the necessary
operational efficiencies and internal peer review are in order to overcome barriers to conducting
a broad portfolio of scientifically important and relevant clinical trials and to ensuring appropriate
enrollment to these trials.

## Key facts

- **NIH application ID:** 10246570
- **Project number:** 3U10CA180868-07S2
- **Recipient organization:** NRG ONCOLOGY FOUNDATION, INC.
- **Principal Investigator:** WALTER J. CURRAN
- **Activity code:** U10 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $140,205
- **Award type:** 3
- **Project period:** 2014-04-17 → 2025-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10246570

## Citation

> US National Institutes of Health, RePORTER application 10246570, NRG Oncology Network Group Operations Center (3U10CA180868-07S2). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10246570. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*